CRISPR Therapeutics (CRSP) PT Lowered to $49 at Stifel
Tweet Send to a Friend
(Updated - February 13, 2025 10:02 AM EST)
Stifel analyst Benjamin Burnett lowered the price target on CRISPR Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Benjamin Burnett lowered the price target on CRISPR Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
